Moderna’s mRNA flu vaccine outperforms standard shot in Phase 3 trial

NEJM study shows strong protection across strains

FDA grants breakthrough status to Laguna's mRNA blood test for schizophrenia diagnosis

The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay

Laguna Diagnostics secures FDA breakthrough tag for mRNA test in psychiatric diagnosis

The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder

Moderna launches late-stage trial of mRNA bird flu vaccine

The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone

Moderna to reveal late-breaking data on flu & RSV mRNA vax at ESCMID 2026

The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21

GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership

BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies

The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission

Moderna signs five-year strategic mRNA vaccine pact with Mexico

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security

Hongene Biotech bags Gates Foundation grant to boost global mRNA vaccine access

Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment

Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half

The study evaluated patients with stage III/IV melanoma after complete tumor resection